Has Jonathan Wise received payments from drug or device companies?

Yes. Drug and device makers reported $20,369 in general payments to Jonathan Wise across 206 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Wise did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Wise come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Wise

Endocrinology, Diabetes & Metabolism · Metairie, LANPI 1932186483

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $15,260 of the $20,369 with a category attached, or 74.9%. AstraZeneca accounts for 75.0% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $16,306 and has fallen 90.6% since, to $1,535 in 2021.

$20,369in general payments, 2019–2025

Across 206 payments — averaging $98.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$15K
Bayer$2K
Eli Lilly$903
Novo Nordisk$693
Novartis$401
Abbott$266
plus $1K from 15 others

$510,566in research payments, 2019–2025

Across 181 payments — averaging $2820.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bayer$269K
AstraZeneca$80K
Novartis$35K
Shire North American Group Inc$35K
GSK$26K
Amgen$24K
plus $40K from 4 others

What the payments were for

Speaking & faculty fees$15,26075%
Travel & lodging$1,5858%
Food & beverage$3,49517%
Education$290%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	40	$15,268
Bayer	2	$1,554
Eli Lilly	4	$903
Novo Nordisk	52	$693
Novartis	5	$401
Abbott	20	$266
Johnson & Johnson(2 entities)	15	$225
Sanofi-aventis U.S. LLC	12	$169
Lilly USA, LLC	13	$157
AbbVie(2 entities)	4	$151
Merck	11	$129
Boehringer Ingelheim	5	$101
Amgen	5	$91
Corcept Therapeutics	5	$78
Medtronic	4	$52
Amarin Pharma, Inc.	2	$32
Radius Health, Inc.	2	$27
Amneal Pharmaceuticals LLC	2	$27
BD	1	$18
Pfizer	1	$17
Dexcom, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FARXIGA$14,773
Kerendia$1,535
Ozempic$125

How this compares

$20,369 in reported general payments places this provider in the 80th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.

See all endocrinology, diabetes & metabolism providers in Louisiana →

Other endocrinology, diabetes & metabolism in Metairie

Julie TalaveraMetairie$49K
Tuan Huy TranMetairie$34K
Joseph MurrayMetairie$7K
Miguel RiveraMetairie$7K
Escipion PedrozaMetairie$2K
Timothy GilbertBaton Rouge$985K
Vivian FonsecaNew Orleans$658K
Abdul KhanHammond$587K
Marideli ScanlanMarrero$444K
Justin FontenotLafayette$397K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →